Neuronetics Inc (STIM)
NASDAQ:STIM
Want to see STIM full AI Analyst Report?
STIM Stock Chart & Stats
$1.42
-$0.02(-1.30%)
At close: 4:00 PM EST
$1.42
-$0.02(-1.30%)
Day’s Range― - ―
52-Week Range$0.80 - $4.85
Previous CloseN/A
Volume92.55K
Average Volume (3M)2.13M
Market Cap
$117.59M
Enterprise Value$172.55M
Total Cash (Recent Filing)$34.36M
Total Debt (Recent Filing)$90.30M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 05, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding69,579,506
10 Day Avg. Volume2,260,318
30 Day Avg. Volume2,125,807
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market Cap1.47
Enterprise Value/Revenue1.16
Enterprise Value/Gross Profit2.39
Enterprise Value/Ebitda-6.17
Forecast
1Y Price Target
$3.00Price Target Upside111.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$162.47M
Bulls Say, Bears Say
Bulls Say
LeadershipAnalyst views the appointment of Dan Reuvers as CEO as a strong leadership move given his experience and the firm's improving revenues that bring it closer to profitability.
Operational PerformanceThe combined company achieving positive cash flow from operations supports the view that scale strengthens the business and reduces operating cash burn.
PartnershipsA collaboration with Compass Pathways to offer COMP360 leverages vertical integration and expands the company’s depression treatment platform, enhancing commercial reach.
Bears Say
Corporate Structure UncertaintyAn independent shareholder calling for a review of strategic alternatives, including a potential sale of the TMS business, creates uncertainty about the company's structure and long-term strategy.
Guidance GapManagement providing no forward guidance leaves the company's future revenue trajectory unclear and may increase investor uncertainty about growth visibility.
Valuation PressureAnalyst lowering the price target and repositioning the firm into a micro-cap med‑tech peer group signals a more conservative valuation backdrop that could weigh on the stock.
Neuronetics News
STIM FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was $0.80 and its highest was $4.85 in the past 12 months.
What is Neuronetics Inc’s market cap?
Neuronetics Inc’s market cap is $117.59M.
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is May 05, 2026 which is in 10 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on Mar 17, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.106 by $0.006.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Undervalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -0.17.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 69,579,506 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.106. Following the earnings report the stock price went down -9.926%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Currently, no hedge funds are holding shares in STIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (111.27% Upside)
$3.00 (111.27% Upside)
Blogger Sentiment
Bullish
STIM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 533.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.23%
12-Months-Change
Fundamentals
Return on Equity
-138.87%
Trailing 12-Months
Asset Growth
0.46%
Trailing 12-Months
Company Description
Neuronetics Inc
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
STIM Company Deck
STIM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated meaningful commercial progress from the Greenbrook integration (strong pro forma revenue growth, treatment volume expansion, improved referral network, NeuroStar capital momentum, and positive Q4 operating cash flow) alongside clear near-term challenges (gross margin compression from clinic mix, ongoing legal inquiry, expected negative operating cash flow in FY2026 before H2 recovery, and reimbursement uncertainty for new therapies). Management provided guidance for growth (2026 revenue $160M–$166M, midpoint >9% YoY), a path to reduced operating expenses and positive operating cash flow in the back half of 2026, and strategic optionality via the COMPASS collaboration—overall the positives around growth, integration progress, and improving cash metrics were emphasized, tempered by notable execution, margin, and regulatory risks.View all STIM earnings summariesSTIM Stock 12 Month Forecast
Average Price Target
$3.00
▲(111.27% Upside)
Technical Analysis
Ownership Overview
50.61% Insiders
5.33% Mutual Funds
0.11% Other Institutional Investors
37.63% Public Companies and
Individual Investors